株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

プロトンポンプ阻害剤の世界市場 - 成長、動向、予測(2019年~2024年)

Proton Pump Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 391447
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
プロトンポンプ阻害剤の世界市場 - 成長、動向、予測(2019年~2024年) Proton Pump Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 115 Pages
概要

プロトンポンプ阻害剤市場の主な成長要因には、胃食道逆流章(GERD)の罹患数の増加および新規ドラッグデリバリーシステムの普及などが挙げられます。

当レポートでは、世界のプロトンポンプ阻害剤市場を調査し、市場の概要、医薬品タイプ・地域別の市場規模の推移と予測、市場の成長要因および阻害要因、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場の成長要因
    • 胃食道逆流症(GERD)の罹患数の増加
    • 新規ドラッグデリバリーシステムの普及
  • 市場の阻害要因
    • ジェネリック医薬品の利用増加
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • 医薬品タイプ別
    • OTC医薬品
    • 処方箋医薬品
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • AstraZeneca
    • Bayer AG
    • Cadila Pharmaceuticals
    • Eli Lilly and Company
    • エーザイ
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Pfizer Inc.
    • Santarus Inc.
    • 武田薬品工業

第7章 市場機会と将来展望

目次
Product Code: 52932

Market Overview

The major factors for the growth of the proton pump inhibitors market include the increasing prevalence of gastroesophageal reflux disease (GERD) and the rising acceptance of novel drug delivery systems.

Gastroesophageal reflux disease is a chronic condition, where the stomach content comes back up into the esophagus resulting in either symptoms or complications. The most frequently reported symptoms of GERD are heartburn, a burning discomfort that begins behind the breastbone and radiates to the neck and throat, and acid regurgitation, which is characterized as a bitter, sour-tasting fluid.

In addition to the increase in prevalence, people with risk factors, such as obesity, tobacco use, and others, are also increasing in almost every part of the world. Obesity, which is the major risk factor of GERD, is increasing rapidly in developed countries, such as the United States, the United Kingdom, and others. The increasing prevalence of GERD, along with the growing risk factor population, is likely to lead to the growth in the demand for proton pump inhibitors, which in turn, will drive the market. Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitors market.

Scope of the Report

As per the scope of the report, proton pump inhibitors (PPIs) are a group of drugs, whose main action is the long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. The market studied is further segmented on the basis of drug type and geography. The drug type segmentation includes OTC and prescription drugs.

Key Market Trends

Esomeprazole is Expected to Account for the Largest Market Share in Drug Type

Nexium is one among the leading revenue generating drugs globally, and it is used to treat the symptoms of GERD, heartburn, and other disorders involving excessive stomach acids. The drug was being sold as a prescriptive drug till before 28th March 2014, the date when FDA approved it as an OTC drug. The shift from being a prescription-only drug to being sold as an over-the-counter (OTC) drug is likely to be a major driving force for the sales of the drug in the near future. There are several benefits associated with OTC drugs, such as low price, enhanced accessibility, and no regular monitoring. As OTC drugs are sold without any prescription, the consumer need not go to any doctor for a prescription, which reduces the overall cost, and hence these drugs have the potential to increase their adoption rate. Accessibility is another vital factor for the consumption of any medicine, and better accessibility may definitely result in more revenue. However, OTC drugs have some disadvantages as well. As they can be purchased without any prescription, anyone can buy as many as they want and leave the scope for their overuse.

Additionally, there are several minor side effects, such as nausea, headaches, dry mouth, diarrhea, allergic reaction, and others, as well as some major side effects, such as kidney disease, dementia, and others associated with its use, which can affect the adoption rate, and hence can be the restraining factors for the growth of the market.

North America Accounted for the Largest Share in the Global Market

North America holds a major share in the proton pump inhibitors market and is expected to show a similar trend over the forecast period, without significant fluctuations. There is a rising prevalence of GERD in the United States, Canada, and Mexico. Furthermore, GERD affects up to 20% of adults in the United States, therefore making the disease an important concern. Proton pump inhibitors are the widely prescribed drugs, and increased PPI use has been observed in the US ambulatory settings. Furthermore, many firms are expected to spend heavily on promoting their brands. The widespread use of these has recently gained attention from the American Board of Internal Medicine's campaign to promote the appropriate use of PPIs.

Competitive Landscape

The proton pump inhibitors market is a fragmented one, owing to the presence of various players in the market. The market players are focusing on acquiring the market share by focusing on aggressive advertisements and awareness programs among the patients. The major key players in the market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, and Pfizer.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Gastroesophageal Reflux Disease (GERD)
    • 4.2.2 Rising Acceptance of Novel Drug Delivery Systems
  • 4.3 Market Restraints
    • 4.3.1 Increasing Use of Generic Products
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 OTC (Over-the-Counter) Drugs
      • 5.1.1.1 Omeprazole
      • 5.1.1.2 Lansoprazole
      • 5.1.1.3 Esomeprazole
      • 5.1.1.4 Other OTC Drugs
    • 5.1.2 Prescription Drugs
      • 5.1.2.1 Rabeprazole
      • 5.1.2.2 Dexlansoprazole
      • 5.1.2.3 Pantoprazole
      • 5.1.2.4 Other Prescription Drugs
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 US
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 UK
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca
    • 6.1.2 Bayer AG
    • 6.1.3 Cadila Pharmaceuticals
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 Eisai Inc.
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Santarus Inc.
    • 6.1.10 Takeda Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top